Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.
Journal article
Oxford University Press (OUP)
2022-05-04T00:00:00+00:00
225
1500 - 1503
3